These health startups raised $124M in venture capital funding this week
Although the Covid-19 pandemic has continued its relentless spread across the globe, several startup companies have closed venture capital funding rounds this week.
UK-based KaNDy Therapeutics raises $32.5 million Series C round, led by US firm
Longitude Capital leads round worth £25 million, which KaNDy will use to advance its non-hormonal menopause drug into Phase IIb clinical trial this year.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Biotech fund manager Sam Isaly accused of behaving like no one told him the 80s had ended
We are increasingly aware that most of the behavior evinced by men in power is beyond logic, but what OrbiMed Adivsors founder and managing partner Sam Isaly is said to have done is sad and retro.
OrbiMed’s secret sauce: A Q&A with Founder Samuel Isaly (Part One)
"People who punch time cards are not likely those who discover new drugs," OrbiMed Managing Partner Samuel Isaly said in a fascinating discussion at the BIO CEO conference in New York.
OrbiMed-backed LogicBio raises $4M for hemophilia gene therapy
Fledgling startup LogicBio Therapeutics has raised $4 million from OrbiMed Advisors for its hemophilia gene therapy therapeutic candidate.
Guardant Health announced an almost $100M Series D round for its cancer blood test
The Redwood City, Calif.-based company has raised nearly $100 million in Series D financing led by OrbiMed Advisors.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Healthcare venture firm OrbiMed launching $300M Israeli investment fund
If it's anything like its first fund, OrbiMed's new Israeli investment fund will invest $5 million to $20 million in each of 12 to 15 companies - much like the first fund.
OrbiMed draws in more healthcare strategics in nearly $1 billion royalty and credit fund
Healthcare investor OrbiMed announced its second debt and royalty fund on Monday and continued to expand efforts to add more healthcare institutions as investors. The $924 million OrbiMed Royalty Opportunities II will invest between $20 million to $150 million per company. OrbiMed’s various investment funds total $14 billion and cover all of healthcare’s various sectors. […]
Main reason startups get rejected by venture capital: “Crappy teams”
The biggest reason startups get turned down by venture capital? They’ve got “crappy teams,” said Peter Thompson, a private equity partner at OrbiMed – one of the largest healthcare investment firms in the country. Thompson spoke with some candor at a recent Q&A sponsored by J-Labs San Diego. Here’s what he said, edited for clarity: What’s the biggest reason venture […]
GE invests in Afib market, helps minimally invasive imaging and mapping startup close $28M Series B round
The growing A-fib market continues to gain the attention of the major players this week: GE Ventures helped Acutus Medical to close a $28 million Series B round. The San Diego-based startup is working to develop a minimally invasive, real-time 3-D Cardiac Chamber Imaging and Dipole Density Mapping system. This technology could help physicians locate […]
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
These are the most active VCs in healthcare since 2012
As investments in life science companies have dipped over the past few years, some investors have scaled back investments or walked away from the sector all together. But based on a tally by investment research firm PitchBook in its 2013 Venture Capital Healthcare Report, several firms have made 10 or more investments in pharmaceutical, medical […]
Relypsa snatches $80M for drug to treat high potassium in kidney disease, diabetes
Patients with kidney disease, diabetes and heart failure can develop elevated potassium levels that can lead to serious complications. Relypsa - which has secured nearly $200 million since its founding - plans to take its drug to phase 3 trials this year.
‘Universal blood’ technology coming from Velico Medical
Velico Medical Inc. sold some of its royalty rights to OrbiMed Advisors LLC for an unspecified amount. CFO Tom Fitzgerald told MassDevice.com that the Beverly, Mass.-based firm plans to use the cash to shift its focus from developing its flagship “universal blood” technology to a pair of technologies it thinks it can bring to market […]
Lung disease diagnostics company superDimension lands $25M
superDimension Inc. has raised $24.8 million, according to a report in Israeli media. The startup based in Plymouth, Minnesota, with offices in Israel and Germany is developing GPS-like technology designed to detect early stages of lung cancer.
Athersys board member resigns
As of Sept. 9, Michael Sheffery, a general partner with New York-based venture firm OrbiMed Advisors, no longer is a member of Athersys' board.